moxifloxacin has been researched along with ethidium bromide in 5 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (ethidium bromide) | Trials (ethidium bromide) | Recent Studies (post-2010) (ethidium bromide) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 116 | 0 | 68 |
| Protein | Taxonomy | moxifloxacin (IC50) | ethidium bromide (IC50) |
|---|---|---|---|
| Telomerase reverse transcriptase | Homo sapiens (human) | 2.59 | |
| Thiosulfate sulfurtransferase | Homo sapiens (human) | 0.83 | |
| 60 kDa chaperonin | Escherichia coli | 2.4 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2 | |
| 10 kDa chaperonin | Escherichia coli | 2.4 | |
| putative polyprotein | 2.4395 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Courvalin, P; Galimand, M; Périchon, B | 1 |
| Bradbury, BJ; Cheng, J; Deshpande, M; Pucci, MJ; Thanassi, JA; Thoma, CL | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
5 other study(ies) available for moxifloxacin and ethidium bromide
| Article | Year |
|---|---|
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2007 |
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Mutation; Quinolones; Staphylococcus aureus; Thiazoles; Topoisomerase II Inhibitors | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |